| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
ARTICLE |
Correspondence to:
Correspondence to:
Professor David A Wood
Cardiovascular Medicine, National Heart and Lung Institute, Imperial College, Charing Cross Hospital, 5th Floor, Laboratory Block, Fulham Palace Road, London W6 8RF, UK; d.wood@imperial.ac.uk
Keywords: Joint British Societies; cardiovascular disease prevention; Joint British Societies’ guidelines; prevention of cardiovascular disease; clinical practice
| The first 150 words of the full text of this article appear below. |
PREFACE
The Joint British Societies’ guidelines (JBS 2) on cardiovascular disease prevention in clinical practice were developed by a Working Party (see table) with nominated representatives from six professional societies. All members contributed to the text and those from the specialist societies of hypertension, lipids, and diabetes were specifically responsible for developing the sections on blood pressure, lipids, and glucose. All sections of the document represent an evidence based consensus by all professional societies involved. The scientific literature which informs the recommendations is referenced throughout the text and Dr Kornelia Kotseva is thanked for all her help in searches for systematic reviews and meta-analyses, and checking the referencing of all sections. We are grateful to both Mr Harry Heyes of the Department of Medical Illustration, University of Manchester, for the cardiovascular risk prediction charts artwork, and Mr Daniel Prais of Crawford’s Business Services, Salford, for the computer programming. Dr Paola Primatesta
Related Articles
Heart 2007 93: 257.
Heart 2007 93: 116.
This article has been cited by other articles:
|
|
 |
|
  L. Hooper, P. A Kroon, E. B Rimm, J. S Cohn, I. Harvey, K. A Le Cornu, J. J Ryder, W. L Hall, and A. Cassidy Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials Am. J. Clinical Nutrition, July 1, 2008; 88(1): 38 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wild and C. D Byrne Time to rethink high-density lipoprotein? Heart, June 1, 2008; 94(6): 692 - 694. [Full Text] [PDF]
|
|
|
|
 |
|
 S.H. Song and C.A. Hardisty Diagnosing metabolic syndrome in type 2 diabetes: does it matter? QJM, June 1, 2008; 101(6): 487 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Gray, A Jaiyeola, M Whiting, M Modell, and A S Wierzbicki Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre Heart, June 1, 2008; 94(6): 754 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. P Cappuccio Commentary: Controversies in NICE guidance on lipid modification for the prevention of cardiovascular disease BMJ, May 31, 2008; 336(7655): 1248 - 1249. [Full Text] [PDF]
|
|
|
|
|
|
J Armitage Commentary on NICE technology appraisal guidance on ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia Heart, May 1, 2008; 94(5): 643 - 645. [Full Text] [PDF]
|
|
|
|
 |
|
 O. van Hecke Whose line is it anyway? Psychiatr. Bull., May 1, 2008; 32(5): 198 - 198. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Petty and D. Lloyd Can cheap generic statins achieve national cholesterol lowering targets? J Health Serv Res Policy, April 1, 2008; 13(2): 99 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Peter, A Cox, and M Evans Management of diabetes in cardiovascular patients Heart, March 1, 2008; 94(3): 369 - 375. [Full Text] [PDF]
|
|
|
|
|
|
J.V. Patel, H.S. Lim, A. Gunarathne, I. Tracey, P.N. Durrington, E.A. Hughes, and G.Y.H. Lip Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes mellitus QJM, March 1, 2008; 101(3): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K-K Lau, Y-H Chan, K-H Yiu, S Tam, S-W Li, C-P Lau, and H-F Tse Incremental predictive value of vascular assessments combined with the Framingham Risk Score for prediction of coronary events in subjects of low-intermediate risk Postgrad. Med. J., March 1, 2008; 84(989): 153 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Ruiz-Nodar, F. Marin, J. A. Hurtado, J. Valencia, E. Pinar, J. Pineda, J. R. Gimeno, F. Sogorb, M. Valdes, and G. Y.H. Lip Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation: Implications for Bleeding Risk and Prognosis J. Am. Coll. Cardiol., February 26, 2008; 51(8): 818 - 825. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. B. D'Agostino Sr, R. S. Vasan, M. J. Pencina, P. A. Wolf, M. Cobain, J. M. Massaro, and W. B. Kannel General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study Circulation, February 12, 2008; 117(6): 743 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A J Turley, V Chen, and J A Hall Simultaneous presentation of coronary heart disease in identical twins Postgrad. Med. J., February 1, 2008; 84(988): 100 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. Seidel and N. Stocks Estimating Cardiovascular Risk Arch Intern Med, January 14, 2008; 168(1): 111 - 111. [Full Text] [PDF]
|
|
|
|
|
|
D. Preiss and N. Sattar Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence Heart, December 1, 2007; 93(12): 1493 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E Clark, J. L Campbell, R. J Powell, and J. F Thompson The inter-arm blood pressure difference and peripheral vascular disease: cross-sectional study Fam. Pract., October 1, 2007; 24(5): 420 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D Sleath Here's to risk assessment BMJ, September 22, 2007; 335(7620): 577 - 578. [Full Text] [PDF]
|
|
|
|
|
|
A. Woodward, D. Bayley, L. Overend, and G. Gill Antiplatelet drug use in a diabetic clinic QJM, September 1, 2007; 100(9): 547 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P J Twomey and D R Pledger HDL-cholesterol and triglycerides: an overlooked issue? J. Clin. Pathol., September 1, 2007; 60(9): 1065 - 1066. [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. M. Saweirs and J. Goddard What are the best treatments for early chronic kidney disease?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix31 - ix38. [Full Text] [PDF]
|
|
|
|
|
|
R. Hall, P. M Saukko, P. H Evans, N. Qureshi, and S. E Humphries Assessing family history of heart disease in primary care consultations: a qualitative study Fam. Pract., August 28, 2007; (2007) cmm037v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Harper, A. Hodsman, J. Gilg, D. Ansell, and A. J. Williams Factors which may influence cardiovascular disease in dialysis and transplant patients blood pressure (Chapter 10) Nephrol. Dial. Transplant., August 1, 2007; 22(suppl_7): vii119 - vii137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D Deepak, N J Furlong, J P H Wilding, and I A MacFarlane Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease Postgrad. Med. J., April 1, 2007; 83(978): 277 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Chauhan Cardiovascular disease prevention in primary care Br. Med. Bull., March 5, 2007; (2007) ldm002v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, H. M. Murray, A. McConnachie, G. J. Blauw, E. L.E.M. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, et al. C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation, February 27, 2007; 115(8): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Heart Protection Study Collaborative Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people BMJ, December 2, 2006; 333(7579): 1145 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Brindle, A Beswick, T Fahey, and S Ebrahim Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review Heart, December 1, 2006; 92(12): 1752 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Spoken sessions Thorax, December 1, 2006; 61(suppl_2): ii3 - ii56. [Full Text] [PDF]
|
|
|
|
|
|
B. Williams The Year in Hypertension J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1698 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
D G. Mackenzie, S. H Wild, and P. Rutledge Are eligibility criteria for over the counter statins appropriate? BMJ, September 30, 2006; 333(7570): 704 - 704. [Full Text] [PDF]
|
|
|
|
|
|
P Mcelduff, M Jaefarnezhad, and P N Durrington American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively Heart, September 1, 2006; 92(9): 1213 - 1218. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Statins for primary prevention in type 2 diabetes DTB, August 1, 2006; 44(8): 57 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G Duerden Should we lower cholesterol as much as possible?: Policy on high dose statins is startlingly absent. BMJ, June 17, 2006; 332(7555): 1452 - 1453. [Full Text]
|
|
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
